| A review of carbamazepine's hematologic reactions and monitoring recommendations. | |
| | |
MedLine Citation:
|
PMID: 2089834 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Early case reports of fatal hematologic effects attributed to carbamazepine (CBZ) resulted in extensive monitoring recommendations by the manufacturer. The rarity of blood dyscrasias led many authors to question the manufacturer's guidelines. Thus the manufacturer removed specific monitoring guidelines, allowing physicians to monitor CBZ using their clinical judgment. This article reviews case reports and studies of CBZ's hematologic effects. Due to their rapid onset, daily laboratory checks would be necessary to monitor for aplastic anemia, agranulocytosis, and thrombocytopenia. These adverse effects are best monitored by informing patients and physicians to carefully watch for signs and symptoms. Leukopenia develops more slowly, occurring in approximately 12 percent of children and 7 percent of adults. Its onset is typically within the first three months of treatment, with patients at risk having a low or low-normal pretreatment white blood cell (WBC) count. Leukopenia often reverses, even if CBZ is continued. Based upon our review of the literature, we recommend monitoring of those high-risk patients during the first three months of treatment with the frequency being determined by results of each laboratory value. WBC counts less than 3000/mm3 or neutrophil counts below 1000/mm3 warrant a decrease in dose with frequent monitoring or CBZ discontinuation, if necessary. |
| | |
Authors:
|
J L Sobotka; B Alexander; B L Cook |
Related Documents
:
|
19661174 - Pseudopathologic brain parenchymal enhancement due to venous reflux from left-sided inj... 20505834 - Periorbital edema secondary to imatinib mesylate. 11343604 - Excessive yawning and ssri therapy. 20926454 - Toxic encephalopathy in elderly patients during treatment with capecitabine: literature... 22953444 - Diagnosis and management of moderate and severe traumatic brain injury sustained in com... 7844374 - Antimicrobial-resistant epidemic shigella dysenteriae type 1 in zambia: modes of transm... |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review |
Journal Detail:
|
Title: DICP : the annals of pharmacotherapy Volume: 24 ISSN: 1042-9611 ISO Abbreviation: DICP Publication Date: 1990 Dec |
Date Detail:
|
Created Date: 1991-05-30 Completed Date: 1991-05-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8904338 Medline TA: DICP Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1214-9 Citation Subset: IM |
Affiliation:
|
University of Iowa, College of Pharmacy, Iowa City 52242. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Agranulocytosis / chemically induced* Anemia, Aplastic / chemically induced* Carbamazepine / adverse effects* Child, Preschool Female Humans Male Middle Aged Product Surveillance, Postmarketing* Risk Factors Thrombocytopenia / chemically induced |
| Chemical | |
Reg. No./Substance:
|
298-46-4/Carbamazepine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemolytic reactions to nitrofurantoin in patients with glucose-6-phosphate dehydrogenase deficiency:...
Next Document: A nationwide survey of antibiotic prescribing patterns and clinical outcomes in patients with bacter...